Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020
Flexion Therapeutics (Nasdaq:FLXN) will release its third-quarter 2020 financial results on November 4, 2020, after U.S. market close. The company previously held a conference call on October 13, 2020, where preliminary net sales were discussed. A replay of the call is accessible via Flexion's corporate website. Flexion focuses on developing innovative local therapies for musculoskeletal conditions, particularly osteoarthritis. This announcement is pivotal for investors monitoring the company's performance in the biopharmaceutical sector.
- None.
- None.
BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020.
The company hosted a conference call on October 13, 2020, in conjunction with reporting preliminary third-quarter net sales. A replay of that call is available on Flexion’s corporate website: https://ir.flexiontherapeutics.com/events-and-presentations.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The ompany's core values are focus, ingenuity, tenacity, transparency and fun. Visit flexiontherapeutics.com.
Contact:
Scott Young
Vice President, Corporate Communications & Investor Relations
T: 781-305-7194
syoung@flexiontherapeutics.com
FAQ
When will Flexion Therapeutics report its Q3 2020 financial results?
What did Flexion announce on October 13, 2020?
How can investors access the replay of the Flexion conference call?
What is Flexion Therapeutics' primary focus?
